source
- Merck partners with Sarah Cannon to accelerate community oncology trialsMerck and Sarah Cannon Research Institute announced a collaboration to improve patient access to oncology trials at community sites across the United States. The partnership will use SCRI’s Accele…
- BioMarin to acquire Alesta Therapeutics for $275 million to expand bone disease pipelineBioMarin Pharmaceutical announced it will purchase Alesta Therapeutics for an upfront payment of $275 million. Alesta is developing an oral small-molecule drug, ALE1, aimed at treating hypophospha…